Ozempic is synonymous with weight loss for many people. Doctors explain benefits and risks of semaglutide and other GLP-1 ...

Hims & Hers offers a copycat of the blockbuster weight-loss drug at a fraction of the cost. But it might be a short-lived ...

WVU Medicine is playing a lead role in a national clinical study of a minimally invasive surgical procedure for people who've ...

Eli Lilly and Company's impressive Q4 earnings driven by tirzepatide's success, diverse portfolio, and promising pipeline.

In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...

The use of blockbuster weight loss drugs has surged among young women, for whom the treatments can often be "liberating." ...

The study lasts up to five weeks and involves four to five visits to the Center for Human Nutrition. The study involves measuring body composition, sleep, mood, diet and other aspects of health.

When Jeanne began to seriously consider taking Zepbound, one of the new-generation weight-loss drugs, she had the briefest of ...

The FDA announced in late December that it had approved Eli Lilly's Zepbound (tirzepatide) for the treatment of moderate to severe OSA in adults with obesity. It’s approved for use in combination with ...

Copyright 2025 The Associated Press. All Rights Reserved. A new poll from The Associated Press-NORC Center for Public Affairs Research looks at what U.S. adults think ...

The results, out after market close yesterday evening, came more than a month after the FDA approved Eli Lilly’s GLP-1 drug Zepbound (tirzepatide) as the first and only prescription drug to ...